Arcadia Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Arcadia Biosciences, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>

AI Summary

Arcadia Biosciences, Inc. (RKDA) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Arcadia Biosciences, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing is from Arcadia Biosciences, Inc., with Central Index Key 0001469443. The company's business address is 202 Cousteau Place, Suite 105, Davis, CA 95618. The fiscal year end for Arcadia Biosciences, Inc. is December 31. The filing was submitted on May 13, 2024.

Why It Matters

For investors and stakeholders tracking Arcadia Biosciences, Inc., this filing contains several important signals. This 10-Q filing provides an update on the company's financial performance and operational status for the first quarter of 2024. Investors and stakeholders can use this report to assess the company's current financial health, strategic direction, and potential risks.

Risk Assessment

Risk Level: — Arcadia Biosciences, Inc. shows moderate risk based on this filing. The filing is a standard 10-Q, which is a routine quarterly report and does not indicate any immediate or significant financial distress or unusual events.

Analyst Insight

Monitor future filings for detailed financial results and strategic updates from Arcadia Biosciences, Inc.

Key Numbers

• 2024-03-31 — Period End Date (Conformed Period of Report)
• 2024-05-13 — Filing Date (Filed as of Date)

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Filer
• 0000950170-24-058563 (other) — Accession Number
• 20240331 (date) — Conformed Period of Report
• 20240513 (date) — Filed as of Date
• 0001469443 (other) — Central Index Key
• 202 COUSTEAU PLACE, SUITE 105, DAVIS, CA 95618 (address) — Business Address

FAQ

Industry Context

Arcadia Biosciences operates in the agriculture technology sector, focusing on crop improvement and development.

Regulatory Implications

The filing is a standard 10-Q, adhering to SEC regulations for quarterly financial reporting.

What Investors Should Do

1. Review the full 10-Q document for detailed financial statements and management discussion.
2. Analyze any disclosed risk factors and their potential impact on the company.
3. Compare the reported figures with previous quarters and industry benchmarks.

Key Dates

• 2024-03-31: Quarter End — End of the reporting period for the 10-Q filing.
• 2024-05-13: Filing Date — Date the 10-Q was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the quarterly update for March 31, 2024, following previous filings for the company.

Key Financial Figures

• $0.001 — 840 shares of common stock outstanding, $0.001 par value per share. Arcadia Bioscien

Filing Documents

• rkda-20240331.htm (10-Q) — 1810KB
• rkda-ex31_1.htm (EX-31.1) — 13KB
• rkda-ex31_2.htm (EX-31.2) — 13KB
• rkda-ex32_1.htm (EX-32.1) — 8KB
• rkda-ex32_2.htm (EX-32.2) — 8KB
• 0000950170-24-058563.txt (&nbsp;) — 9387KB
• rkda-20240331.xsd (EX-101.SCH) — 1575KB
• rkda-20240331_htm.xml (XML) — 1848KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 Part II — Other Information 25 Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 26

CONDENSED CONSOLID ATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLID ATED FINANCIAL STATEMENTS Arcadia Biosciences, Inc. Condensed Consolida ted Balance Sheets (Unaudited) (In thousands, except share data) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 3,317 $ 6,518 Short-term investments 5,184 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $ 0 as of March 31, 2024 and December 31, 2023 760 514 Inventories — current 1,831 1,958 Assets held for sale 15 51 Prepaid expenses and other current assets 535 807 Total current assets 11,642 14,972 Property and equipment, net 328 384 Right of use asset 695 792 Inventories — noncurrent 3,178 3,354 Intangible assets, net 39 39 Other noncurrent assets 164 164 Total assets $ 16,046 $ 19,705 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 1,732 $ 2,410 Amounts due to related parties 75 58 Operating lease liability — current 801 852 Other current liabilities 270 270 Total current liabilities 2,878 3,590 Operating lease liability — noncurrent 21 155 Common stock warrant and option liabilities 664 1,257 Other noncurrent liabilities 2,000 2,000 Total liabilities 5,563 7,002 Commitments and contingencies (Note 13) Stockholders' equity: Common stock, $ 0.001 par value— 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 1,362,840 and 1,285,337 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 65 65 Additional paid-in capital 284,658 284,515 Accumulated other comprehensive income 161 101 Accumulated deficit ( 274,263 ) ( 271,840 ) Total stockholders' equity 10,621 12,841 Non-controlling interest ( 138 ) ( 138 ) Total stockholders' equity 10,483 12,703 Total liabilities and st

View Full Filing

View this 10-Q filing on SEC EDGAR